News

US regulators are reportedly gearing up to revoke breakthrough status for Bristol-Myers Squibb’s hepatitis C drug daclatasvir, just days after it emerged that Merck & Co’s hep C combo will suffer the same fate.

Advisors to the US Food and Drug Administration will meet at the end of April to review Amgen’s closely-watched oncolytic immunotherapy T-Vec for melanoma.

GSK has acquired GlycoVaxyn, the Swiss vaccine-maker it has held a minority stake in since 2012, paying $190 million in cash to take full ownership.

Sanofi group Genzyme has signed a major deal with gene therapy start-up Voyager Therapeutics, which will see the groups embark on a journey to discover new treatments for serious central nervous system conditions such as Parkinson’s disease.

Two years on from the Mid-Staffs scandal and there are still significant problems in the National Health Service regarding the treatment of whistleblowers, an investigation by Sir Robert Francis has found.

The NGO Doctors of the World (Médecins du Monde) is contesting Gilead Sciences’ intellectual property on Sovaldi as part of a campaign to cut prices on the blockbuster hepatitis C drug.

Advisors to the US Food and Drug Administration will meet next month to review Celltrion’s biosimilar of Johnson & Johnson and Merck & Co’s anti-inflammatory blockbuster Remicade.

Gilead Sciences is to create new UK commercial headquarters in London and expand its existing operations in the country.

The National Health Service could have to support one million more older patients with serious illnesses within the next decade, a new report has warned.

Pfenex and Hospira, which is in the process of being acquired by Pfizer, are teaming up to develop the former’s biosimilar of Roche and Novartis’ eye blockbuster Lucentis.

Roche has hit the acquisition trail again to buy privately-held Signature Diagnostics of Germany.

Takeda’s flagship experimental cancer drug ixazomib is a giant leap closer to being filed with regulatory authorities around the globe for multiple myeloma, after turning in a solid performance in late-stage trials.

University of Queensland spin out Vaxxas has managed to secure equity funding of A$25 million ($20 million) in a new round of financing to help advance a suite of clinical programs and develop a pipeline of new vaccine patches.

Some parts of England will need a 50% increase in community GPs by 2020 to meet the demands of the growing population, the Royal College of General Practitioners has warned.

Shares of Achillion Pharmaceuticals shot up as much as 20% Monday morning as it emerged that patients with hepatitis C taking its investigational therapy were cleared of the virus after just six weeks.